SERA Stock Overview
Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sera Prognostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.96 |
| 52 Week High | US$11.32 |
| 52 Week Low | US$1.52 |
| Beta | 1.49 |
| 1 Month Change | 8.85% |
| 3 Month Change | 61.69% |
| 1 Year Change | 204.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.30% |
Recent News & Updates
Recent updates
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Mar 24Sera Prognostics: The Pregnancy Company On A Hot Streak
Jan 10Is Sera Prognostics (NASDAQ:SERA) In A Good Position To Deliver On Growth Plans?
Oct 03
We Think Sera Prognostics (NASDAQ:SERA) Can Afford To Drive Business Growth
Jun 15We're Keeping An Eye On Sera Prognostics' (NASDAQ:SERA) Cash Burn Rate
Feb 16We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Nov 03A Negative EV Opportunity - Sera Prognostics Has A Chance To Become Standard Of Care In Preterm Birth Risk Screening
Aug 10We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully
Jul 21Here's Why We're Not Too Worried About Sera Prognostics' (NASDAQ:SERA) Cash Burn Situation
Apr 06We're Hopeful That Sera Prognostics (NASDAQ:SERA) Will Use Its Cash Wisely
Dec 15Shareholder Returns
| SERA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | 1.5% | 1.2% |
| 1Y | 204.6% | 1.1% | 24.7% |
Return vs Industry: SERA exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: SERA exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| SERA volatility | |
|---|---|
| SERA Average Weekly Movement | 10.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SERA's share price has been volatile over the past 3 months.
Volatility Over Time: SERA's weekly volatility has decreased from 25% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 56 | Zhenya Lindgardt | seraprognostics.com |
Sera Prognostics, Inc., a women’s health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression.
Sera Prognostics, Inc. Fundamentals Summary
| SERA fundamental statistics | |
|---|---|
| Market cap | US$322.96m |
| Earnings (TTM) | -US$36.24m |
| Revenue (TTM) | US$306.00k |
1,055x
P/S Ratio-8.9x
P/E RatioIs SERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SERA income statement (TTM) | |
|---|---|
| Revenue | US$306.00k |
| Cost of Revenue | US$210.00k |
| Gross Profit | US$96.00k |
| Other Expenses | US$36.34m |
| Earnings | -US$36.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.12 |
| Gross Margin | 31.37% |
| Net Profit Margin | -11,843.79% |
| Debt/Equity Ratio | 0% |
How did SERA perform over the long term?
See historical performance and comparison